Miquel Ensenyat-Mendez

Miquel Ensenyat-Mendez

Auto-generated profile, based on publicly available information

Miquel Ensenyat-Mendez

Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
MDMaggie L. DiNome
Maggie L. DiNome
JOJavier I. J. Orozco
Javier I. J. Orozco
CMChikako Matsuba
Chikako Matsuba
AMAyla O. Manughian-Peter
Ayla O. Manughian-Peter
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
DMDiego M. Marzese
Diego M. Marzese

25 August 2021 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JOJavier Orozco
Javier Orozco
SCShu-Ching Chang
Shu-Ching Chang
CMChikako Matsuba
Chikako Matsuba
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
GGGary L. Grunkemeier
Gary L. Grunkemeier
JGJanie G. Grumley
Janie G. Grumley

5 November 2025 in Research Square
Verified
Preprint
Open access
PDF file
DMDiego M. Marzese
Diego M. Marzese
ALAndrés Felipe Bedoya López
Andrés Felipe Bedoya López
JOJavier Orozco
Javier Orozco
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
BVBetsy Valdez
Betsy Valdez
PAPere Llinàs Arias
Pere Llinàs Arias
Triple-negative breast cancer (TNBC) is a major cause of cancer mortality, with distant metastases presenting a significant clinical challenge. While epigenetic mechanisms like DNA methylation are known to influence TNBC progression, their specific role in driving metastasis remains underexplored. To address this gap, we performed comprehensive multi-omics analysis, integrating epigenomic and transcriptomic profiles from TNBC xenograft models and patient cohorts. Genome-wide DNA methylation profiling of primary tumors, lymph nodes, and lung metastases from xenografts revealed pronounced global hypomethylation in lung lesions, consistent with findings from the clinical cohort. Promoter-methylation changes were enriched in pathways linked to invasion and proliferation, and transcriptomic integration identified 22 epigenetically regulated genes. Among these, elevated AK1 , SLC2A5 , TPI1 , and ZBTB17 expression correlated with a higher risk of lung dissemination. These findings highlight altered DNA methylation as a driver of TNBC lung colonization and identify candidate prognostic markers, emphasizing the importance of epigenetic reprogramming in organ-specific lung metastases.

1 January 2026 in Genes & Diseases
Verified
Journal Article
Open access
SISandra Iñiguez-Muñoz
Sandra Iñiguez-Muñoz
PLPere Llinàs-Arias
Pere Llinàs-Arias
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
ABAndrés F. Bedoya-López
Andrés F. Bedoya-López
MSMaria Solivellas-Pieras
Maria Solivellas-Pieras
DMDiego M. Marzese
Diego M. Marzese

16 April 2022 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
DRDennis Rünger
Dennis Rünger
JOJavier Orozco
Javier Orozco
JLJulie Le
Julie Le
JBJennifer L. Baker
Jennifer L. Baker
MDMaggie L. DiNome
Maggie L. DiNome

Verified
Journal Article
Open access
PDF file
SISandra Iñiguez-Muñoz
Sandra Iñiguez-Muñoz
ALAndrés Felipe Bedoya López
Andrés Felipe Bedoya López
MEMiquel Ensenyat-Mendez
Miquel Ensenyat-Mendez
PAPere Llinàs Arias
Pere Llinàs Arias
SASoo Kyung Ahn
Soo Kyung Ahn
MDMaggie L. DiNome
Maggie L. DiNome
De-escalation of axillary surgery has resulted in the loss of pathologic nodal information, yet the extent of lymph node involvement remains an important determinant of treatment decisions in estrogen receptor-positive (ER+)/HER2− disease. We examined whether primary tumors differed molecularly according to the extent of this regional dissemination. Genome-wide DNA methylation profiling of primary ER+/HER2− tumors from 47 patients with pN1 (n = 29) vs. >pN1 (n = 18) disease showed differences concentrated at promoters of developmental and cell-adhesion genes. By integrating methylomes with transcriptomes from the TCGA-BRCA cohort (n = 148) and clinical outcomes from KM Plotter (RFS, n = 1154; OS, n = 442; DMFS, n = 423), we identified four genes (ARL10, RIC3, CXCL14, KCNH2) showing concordant molecular and clinical associations, from which we derived the Lymph-node Involvement Outcome Numerator (LION) score. Lower LION scores were observed in metastatic lesions from the AURORA US cohort (n = 45). In SCAN-B (n = 3969), lower scores were associated with shorter distant recurrence-free intervals (HR = 0.38; 95% CI 0.23–0.62); this association persisted after adjustment for age, nodal and tumor category but was lost after adjustment for histological grade (HR = 0.83; 95% CI 0.48–1.44), indicating that the score and grade capture overlapping biology. These findings suggest that primary tumors already display coordinated epigenetic and transcriptional alterations associated with the extent of metastatic dissemination.